A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease


AIM. To evaluate the efficacy and safety of a fixed-dose combination of the angiotensin-converting enzyme inhibitor lisinopril 10 mg and the calcium antagonist amlodipine 5 mg (ekvator) in conjunction with rosuvastatin (mertenil). MATERIALS AND METHODS. The investigation enrolled 50 patients (mean age 57.9 years) with essential hypertension. All the patients received the fixed-dose antihypertensive combination. Stable Functional Class I or II exertional angina was in 46% of the patients. The remaining 54% were found to have brachiocephalic atherosclerosis. All the patients had dyslipidemia and were given rosuvastatin. RESULTS. The mean systolic blood pressure (SBP) initially reached 164.26 mm Hg. During the whole follow-up, the reduction in mean SBP generally accounted for 22.6% (p=0.000). At the study inclusion, the mean diastolic blood pressure (DBP) reached 99.38 mm Hg. The total decline in mean DBP was 19.3% (p=0.000). The mean level of total cholesterol (TC) decreased significantly by 32.1% (p=0.000); that of triglycerides (TG) also fell significantly by 31.8% (p=0.04); that of high-density lipoproteins increased insignificantly by 11.1% (p=0.599); that of low-density lipoproteins (LDL) dropped significantly by 47.5% (p=0.000). CONCLUSION. Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery. The use of rosuvastatin in patients with HD concurrent with CHD during 2 months causes positive changes in the blood lipid composition as a significant reduction in the levels of (TC), LDL, and TG.

Full Text

Restricted Access

About the authors

Z M Galeeva

A S Galiavich

Email: agalyavich@mail.ru


  1. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 3-25.
  2. Маколкин В.И. Совершенствование комбинированной терапии - путь к улучшению результатов лечения артериальной гипертонии. Рус мед журн 2007; 16: 1-3.
  3. Фаршанг Ч. Преимущества комбинации лизиноприла и амлодипина при лечении артериальной гипертонии. Гипертония и нефрология. Журнал венгерского Общества Гипертонии и Нефрологии 2005; 21М4, 8 (2): 72-78.
  4. Мешков А.Н. Гиполипидемическая эффективность розувастатина в сравнении с другими статинами. Рац фармакотер в кардиол 2012; 5: 691-693.
  5. Добровольский А.В. Розувастатин - эффективный и безопасный современный гиполипидемический препарат. Рус мед журн 2012; 14: 728-733.
  6. Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Рос кардиол журн 2014; 1: 5-92.
  7. Wald D.S., Law M., Morris J.K. et al.Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122: 290-300.
  8. Corrao G., Parodi A., Zambon A. et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28: 1584-1590.
  9. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55: 399-407.
  10. Claxton A.J., Cramer J., Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
  11. Jamerson K., Weber M.A., Bakris G.L. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
  12. Matsui Y., Eguchi K., O'Rourke M.F. et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54: 716-723.
  13. Преображенский Д.В., Сидоренко Б.А., Шабанова Е.Н. Амлодипин - антагонист кальция третьего поколения. Кардиология 1998; 2: 66-73.
  14. Фельдшерова Н.А., Семернин Е.Н. Амлодипин - обзор клинических исследований. Качествен клин практ 2002; 2: 1-8.
  15. Котовская Ю.В., Лобанкова Л.А. Лизиноприл: основные клинические исследования. Клин фармакол и тер 2002; 4: 49-51.
  16. Кутишенко Н.П., Марцевич С.Ю. Ингибитор ангиопревращающего фермента лизиноприл: особенности применения в кардиологии. Атмосфера. Кардиология 2007; 2: 1-4.
  17. Чазова И.Е., Ратова Л.Г., Недогода С.В. и др. Применение фиксированной комбинации лизиноприла с амлодипином у пациентов с артериальной гипертензией. Системные гипертензии 2012; 1: 47-49.
  18. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Сердце 2005; 4: 3.
  19. Luva A., Mbagaya W., Hall A.S., Barth J.H. Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease. Clinical Medicine Insights. Cardiology 2012; 6: 17-33.
  20. Задионченко В.С., Шахрай Н.Б., Шехян Г.Г. и др. Особенности фармакологических и клинических свойств розувастатина. Рус мед журн 2011; 12: 772-778.
  21. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5: 177-192
  22. Карпов Ю.А. Липидоснижающая терапия как важный компонент в лечении и профилактике сердечно-сосудистых заболеваний. Рус мед журн 2011; 2: 1-6
  23. McKenney J.M., Jones P.H., Adamczyk M.A. et al. Comparison of efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-698.
  24. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prevention and Rehabilitation 2007; 4 (Suppl. 2).
  25. Hunninghake D.B., Stein E.A., Bays H.E. et al. Rosuvastatin improves the atherogenic and artheroprotective lipid profile in patients with hypertriglyceridaemia. Coron Artery Dis 2004; 15: 115-123.



Abstract - 225



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies